856707-38-5

Basic information

• Product Name: CarbaMic acid, [(1S)-1-[1-(acetyloxy)-2-(cyclopropylaMino)-2-oxoethyl]butyl]-, 1,1-diMethylethyl ester (9CI)
• Synonyms: (3S)-3-((tert-butoxycarbonyl)aMino)-1-(cyclopropylaMino)-1-oxohexan-2-yl acetate;CarbaMic acid, [(1S)-1-[1-(acetyloxy)-2-(cyclopropylaMino)-2-oxoethyl]butyl]-, 1,1-diMethylethyl ester (9CI)
• CAS NO: 856707-38-5
• Molecular Formula: C16H29N2O5
• Molecular Weight: 329.41186
• Mol File: 856707-38-5.mol
• Article Data: 17

Chemical Properties

• Appearance: /
• CAS DataBase Reference: CarbaMic acid, [(1S)-1-[1-(acetyloxy)-2-(cyclopropylaMino)-2-oxoethyl]butyl]-, 1,1-diMethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: CarbaMic acid, [(1S)-1-[1-(acetyloxy)-2-(cyclopropylaMino)-2-oxoethyl]butyl]-, 1,1-diMethylethyl ester (9CI)(856707-38-5)
• EPA Substance Registry System: CarbaMic acid, [(1S)-1-[1-(acetyloxy)-2-(cyclopropylaMino)-2-oxoethyl]butyl]-, 1,1-diMethylethyl ester (9CI)(856707-38-5)

Safety Data

• Hazardous Substances Data: 856707-38-5(Hazardous Substances Data)

Upstream product

• 92667-45-3 N-Methylencyclopropylamin 
• 64-19-7 acetic acid 
• 160801-74-1 (2S)-2-(1,1-dimethylethoxycarbonylamino)pentanal 
• 58644-53-4 cyclopropyl isocyanide 
• 4747-72-2 isocyanatocyclopropane 
• 58644-54-5 N-cyclopropylformamide 
• 160801-73-0 (S)-tert-butyl 1-(methoxy(methyl)amino)-1-oxopentan-2-ylcarbamate 
• 53308-95-5 N-tert-butoxycarbonyl-L-norvaline 

Downstream Products

• 850252-34-5 (3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride 

Relevant articles and documents

Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species

Hepatitis is a disease characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically 3% of the world's population. Boceprevir, SCH 503034, (1) our first generation HCV inhibitor, has already established proof-of- concept and is currently in late stage (phase III) clinical trials. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P4 pocket by introducing a new sulfonamide moiety and optimization of the P1/P1′ capping led to the discovery of a novel series of inhibitors of the HCV NS3 serine protease. Optimization of the P1 residue significantly improved potency and selectivity. The combination of optimal moieties led to the discovery of compound 47 which, in addition to being a potent inhibitor of HCV subgenomic RNA replication, was also found to have good PK profile in rat, dog and monkey.

COMPOUNDS THAT INHIBIT PROTEASE CATHEPSIN S AND HCV REPLICATION

The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease,

HCV INHIBITORS

The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.